Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764213 | 0.87 | NAAA (0.59) | NAAA | |
| Trifluoroacetic Acid SCHEMBL23149100 | 0.84 | HTR2C (0.49) | FFAR1 | |
| Trifluoroacetic Acid SCHEMBL23149062 | 0.82 | LMNA (0.43) | POLB | |
| Trifluoroacetic Acid SCHEMBL23148992 | 0.79 | SLC6A4 (0.40) | — | |
| SCHEMBL18764160 | 0.74 | NAAA (0.62) | NAAANPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL17274385 | 0.73 | NAAA (0.65) | NAAA | |
| Trifluoroacetic Acid SCHEMBL29878366 | 0.73 | KDM1A (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL31071587 | 0.73 | SLC6A4 (0.54) | FFAR1 | |
| SCHEMBL3128895 | 0.73 | SLC6A4 (0.56) | — | |
| SCHEMBL16821015 | 0.73 | REN (0.50) | NAAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640494-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof | NORTHEASTERN UNIVERSITY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180222894-A1 | N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA) Inhibitors And Their Use Thereof | NORTHEASTERN UNIVERSITY | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222894-A1 | N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA) Inhibitors And Their Use Thereof | NAAA, NAT1, NAALAD2 | NAAA 1/4885FFAR1 1535/4885NPC1 537/4885 |
| US-10640494-B2 | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof | NAAA, NAT1, NAALAD2 | NAAA 1/4885FFAR1 1535/4885NPC1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.